The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
In Europe, Sun Pharma has always had a focus on developing and offering hospital products in oncology and other areas.
Since the acquisition of Ranbaxy in 2015, a portfolio of retail products was added.
For the European hospital market, Sun aims to develop iv products that are convenient to use, such as Ready-to-Administer products in bags and syringes.
The first result of this initiative is launched in 2016.